CONCLUSIONS
We examined the economic and clinical effects of CVC-CRBSI in
Japan, which has a universal health care insurance system covering all citizens, and found that drug and medical material costs, and
technical fees, were substantially increased. The additional costs of
CVC-CRBSI in Japan were estimated at $57,090 per case. Costs were
influenced by the causative microorganism. Further studies
addressing the limitations of our study are needed.
Acknowledgment
The authors thank the medical editors of the Department of
International Medical Communications of Tokyo Medical University
for conducting the editorial review of the English manuscript.